Laragh's lessons in pathophysiology clinical pearls for treating hypertension

American Journal of Hypertension

Volumn 14, Issue 1, 2001, Pages 84-86

  Laragh, John ^a  

^a American Journal of Hypertension   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0035140134     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(00)01301-7     Document Type: Review

References (19)

1. Rationale for the use of a fixed combination in the treatment of hypertension
2. Treatment and control of high blood pressure in patients treated by general practitioners in France during 1994
3. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1995
4. Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing?
5. Aldosterone secretion and primary and malignant hypertension
6. Electrolyte metabolism and aldosterone secretion in benign and malignant hypertension
7. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II and others on the secretory rate of aldosterone in man
8. The role of aldosterone in man: Evidence for regulation of electrolyte balance and arterial pressure by renal-adrenal system which may be involved in malignant hypertension
9. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases
10. Anti-hypertensive action of propranolol: Specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension
11. 8-angiotensin II for understanding and treatment of high blood pressure
12. Hypertension in man. Exposure of the renin and sodium components using angiotensin II blockade
13. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II for evaluating the renin and sodium factors in hypertensive patients
14. Estimating renin participation in hypertension. Superiority of converting enzyme inhibitor over saralasin
15. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients
16. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme
17. Design of specific inhibitors of angiotensin converting enzyme: New class of orally active agents
18. A new class of angiotensin converting enzyme inhibitors
19. Angiotensin II receptors and angiotensin II receptor antagonists